Why NovImmune moved from ELISA to Gyrolab xP workstation
Anti-Drug Antibodies (ADA) can decrease drug half-life, reduce drug efficacy and even cause serious adverse reactions. Measuring ADA is therefore a key safety concern, but the immunoassays used to do this are complicated by the presence of drug and target in samples, which may severely reduce assay selectivity. This demands immunogenicity assays that are a balancing act between sufficient sensitivity, drug tolerance, and resistance to target interference.
From ELISA to Gyrolab assays
The presentation by Justine Collet, NovImmune SA, at the Informa International Bioanalytical Congress, Berlin, September 9–10, highlighted how moving an ELISA to Gyrolab helped them in this balancing act in the early stages of drug development. Compared to ELISA, the Gyrolab assay delivered 4-fold better sensitivity and 5-fold better drug tolerance with a 5-fold reduction in sample consumption. Her talk was entitled ‘Development of a clinical ADA assay on the Gyrolab platform with appropriate drug and target tolerance for the patient population’.
Find out more about analyzing Anti-Drug Antibodies at NovImmune by downloading a summary of the presentation they held at the Gyrolab User Seminar held in Copenhagen in May, 2014.
You can also learn more about how Gyrolab xP workstation, combined with Bioaffy CDs and dedicated Gyrolab ADA Software, provides an efficient way of optimizing Anti-Drug Antibody analysis by downloading the Product Information Sheet ‘Gyrolab ADA Solution’.